71434-62-3

Upstream product

• 110-53-2 1-Bromopentane 
• 1122-91-4 4-bromo-benzaldehyde 
• 693-25-4 n-pentylmagnesium bromide 
• 5391-88-8 1-(4-bromophenyl)ethanol 
• 71-36-3 butan-1-ol 

Downstream Products

• 7295-46-7 1-(4-bromophenyl)-1-hexanone 
• 836643-56-2 [1-(4-bromo-phenyl)-hexyloxy]-tert-butyl-dimethyl-silane 
• 910562-80-0 1-(4-bromo-phenyl)-hexan-1-ol 4-methoxybenzyl ether 
• 76287-45-1 Tris-(4-n-hexylphenyl)phosphin 
• 23703-22-2 1-bromo-4-n-hexylbenzene 
• 431041-25-7 (-)-(3aS,4S,5R,6aR)-5-hydroxy-4-{4-[(S)-1'-(tert-butyldimethylsilanyloxy)hexyl]phenyl}-5-[tert-butyldimethylsilanyloxy]hexahydropentalen-2-one 
• 431041-23-5 (+)-(3'aS,4'S,5'R,6'aR)-[4'-[4-((S)-1''-(tert-butyldimethylsilanyloxy)hexyl)phenyl]-1',6'a,6',3'a-tetrahydro-5,5-dimethylspiro[1,3-dioxane-2,2']]pentalen-5'-ol 
• 431041-21-3 (-)-[(S)-1-(4-bromophenyl)hexyloxy]tert-butyldimethylsilane 
• 431041-28-0 (-)-(S)-1-p-bromophenyl-1-hexanol 
• 76287-58-6 1-Bromo-4-((E)-hex-1-enyl)-benzene 

Relevant academic research and scientific papers

Ruthenium-catalyzed β-alkylation of secondary alcohols with primary alcohols

The catalytic properties of a series of ruthenium complexes for β-alkylation of secondary alcohols with primary alcohols were studied. The catalytic activities of the ruthenium complexes were found to be dependent on the auxiliary ligands. The most active catalytic precursor found in this study is the ruthenium complex RuCl2(PPh3)2(2-NH2CH2Py) [2-NH2CH2Py = 2-aminomethyl pyridine], which effectively catalyzed the β-alkylation of both aryl- and alkyl-substituted secondary alcohols with benzylic and alkyl primary alcohols.

Tandem α-Alkylation/Asymmetric Transfer Hydrogenation of Acetophenones with Primary Alcohols

Tandem α-alkylation/asymmetric transfer hydrogenation of acetophenones with primary alcohols, mediated by a single ruthenium catalyst, is described. Under optimized reaction conditions and with use of [Ru(p-cymene)Cl2]2 in combination with an amino acid hydroxyamide ligand, the chiral secondary alcohol products were isolated in moderate yields and in moderate to good enantiomeric excess (up to 89 % ee). One catalyst - one pot - two reactions. Acetophenones are initially alkylated with primary alcohols by the borrowing hydrogen methodology. The alkylation products are directly converted to enantiomerically enriched secondary alcohols.

THERAPEUTIC SUBSTITUTED CYCLOPENTANES

Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.

SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS

Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.

Therapeutic Substituted Cyclopentanes

Therapeutic compounds are disclosed herein. ???????????

SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS

Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.

SULFONAMIDES

The present invention provides R, R1, R2, R3, X, c, d, e, f, g, x, y, a, b, z and n are defined in the specification. These compounds are useful in lowering IOP and/or treating glaucoma or providing neuroprotection to the

12-ARYL PROSTAGLANDIN ANALOGS

Compounds comprising the formula (I) are disclosed, wherein Y, A, X, R, D, and n are as described. A compound comprising a prostaglandin EP2 selective agonist wherein the ω-chain comprises a substituted phenyl, wherein at least one substituent

SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS

A compound comprising Formula (I) or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.

A new strategy for the enantioselective synthesis of carba-prostacyclin analogues based on organocopper conjugate addition to a bicyclic azoene and its application to the synthesis of 13,14-dinor-inter-p-phenylene carbacyclin

An enantioselective synthesis of E/Z-13,14-dinor-inter-p-phenylene carbacyclin (E/Z-2d) by a new strategy has been realized that holds the prospect of serving as a general route for carba-prostacyclin analogues. The key intermediate in this synthesis is the bicyclic azoene Ts-9, and the key step is the regio- and stereoselective conjugate addition of the chiral arylcopper compound Cu-8d/P-n-Bu3 to the azoene with formation of hydrazone 7d. Enantioselective synthesis of azoene Ts-9 of 95% ee from ketone 4 was accomplished in four and five steps, respectively. Thus, enantioselective deprotonation of bicyclic ketone 4 with chiral base Li-10 and trapping of lithium enolate 11 with CISiMe3 gave enol ether 12, which was chlorinated with N-chlorosuccinimide (NCS) to afford chloro ketone 13. Alternatively, chloro ketone 13 was also prepared upon chlorination of 11 with NCS. Chloro ketone 13 was converted to chloro hydrazone 14, which upon treatment with a mild base furnished azoene Ts-9. Arylcopper compound 8d of 98% ee was obtained in two steps from alcohol 16, which was prepared by enantioselective reduction of ketone 17 with (-)-diisopinocampheylchloroborane. Carbacyclin derivative E/Z-2d was found to be essentially inactive as an inhibitor of ADP induced human platelet aggregation, having an |C50 of > 10 μmol/L.